Primary Neonatal Outcomes in metformin and MNT g

S. Agarwal1, S. Tiwari1, S. Verma1, P. Taneja1, S. Veeraswamy2, R. Jain3, P. Saxena4, A. Chandrasekar5, B.Natarajan6.1GSVM Medical College, Obstetrics and Gynaecology, Kanpur, India. 2The MGR Tamilnadu Medical University, Obstetrics and Gynaecology, Chennai, India. 3 Jain Hospital & Research Centre Pvt Ltd, Medicine, Kanpur, India. 4 LHMC Medical College, Obstetrics and Gynaecology, New Delhi, India. 5 Madha Medical College and Research Institute, Obstetrics & Gynaecology, Chennai, India.6 SRC Diabetes Centre-, Diabetes, Erode, India

Abstract

Method
A study included pregnant women at 8 to 10 weeks of gestation, divided into two groups based on their blood sugar levels of≥110 mg/dl. Those with high levels ≥110 mg/dl received two different interventions: Metformin-MNT and MNT only. Follow-up outcomes were done until delivery.
Results
Primary Outcomes* The Adverse neonatal composite outcomes in the groups were 35 (37.6%) vs 55 (52.3), which were statistically significant (P = 0.038), but the Primary Maternal hypertension composite outcomes were not significant (9 (9.6%) vs 10 (10.7%), P = 0.80) (Table 1). IUD/Spontaneous abortion 8-28 Weeks and stillbirth are 20 (16) and 12(9.6) in the MNT Group compared to nil in the MNT-Metformin intervention group, which is highly significant.
Conclusion: It’s important to keep maternal 2-hour postprandial blood glucose (PPBG) levels below 110 mg/dL in the 10th week of pregnancy to prevent fetal hyperinsulinemia and improve maternal-fetal health.